CLINICAL TRIAL: A PHASE I TRIAL OF CAPECITABINE RAPIDLY DISINTEGRATING TABLETS

临床试验:卡培他滨快速崩解片的 I 期试验

基本信息

  • 批准号:
    8356676
  • 负责人:
  • 金额:
    $ 0.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-12-01 至 2011-11-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT HYPOTHESIS Oral capecitabine will be well tolerated by pediatric patients with newly diagnosed nondisseminated, intrinsic brainstem gliomas and non-disseminated high-grade gliomas. ISPECIFIC AIMS Primary Objectives: 1. To estimate the maximum tolerated dose (MTD) of capecitabine administered concurrently with radiation therapy (RT) to children with newly diagnosed nondisseminated, intrinsic brainstem gliomas or newly diagnosed non-disseminated high-grade gliomas. 2. To describe the dose-limiting toxicity (ies) of capecitabine administered concurrently with radiation therapy to children with newly diagnosed nondisseminated, intrinsic brainstem gliomas or newly diagnosed non-disseminated high-grade gliomas. Secondary Objectives: 1. To characterize the pharmacokinetics of capecitabine as delivered by Capecitabine Rapidly Disintegrating Tablets in this pediatric patient population. 2. To describe in the context of this phase 1 investigation, the anti-tumor activity of capecitabine and radiation that is observed in children with newly diagnosed nondisseminated, intrinsic brainstem gliomas or newly diagnosed non-disseminated high-grade gliomas. 3. To characterize radiographic changes in non-disseminated, newly diagnosed intrinsic brainstem gliomas and high-grade gliomas treated with radiation and capecitabine using MRI, MRS, perfusion and diffusion imaging and PET scans. III. BACKGROUND AND SIGNIFICANCE Brainstem gliomas are astrocytic neoplasms that occur in the pons, midbrain or medulla of children and adolescents. High-grade astrocytomas of childhood are clinically aggressive, regionally invasive tumors, and children with intrinsic brainstem malignant gliomas have a 1- and 5-year progression-free survival (PFS) of less than 25 and 10%, respectively. Other than radiation therapy, no therapy has demonstrated benefit for these patients. The role of chemotherapy in the treatment of this disease is not clear. Previous studies suggest that the benefit from addition of chemotherapy, when compared to surgery and radiotherapy alone, is modest at best. Clearly, new agents and new approaches to therapy are needed for children with high-grade glial tumors. Capecitabine is converted to 5-fluorouracil (5-FU), with thymidine phosphorylase (TP) as the final and rate limiting enzyme for intra-tumoral activation. Previous studies have correlated capecitabine efficacy with the level of TP expression in both cell culture and human xenograft models. Radiation therapy, a standard component of brain tumor management, has been shown to substantially induce TP in glioblastoma xenografts. Additionally, capecitabine has been shown to be a radiosensitizer as well as an active single agent against metastatic brain lesions. Thus there is a strong rationale for evaluating the combination of capecitabine and radiation in the treatment of primary brain tumors. A favorable therapeutic index may also be achieved, since TP appears to be expressed in far greater amounts in brain tumors compared to normal brain tissue. Initial experience with combination treatment in adults indicates that treatment is well tolerated with no unexpected or additive toxicities seen.
这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的, 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量, 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 摘要 假设 口服卡培他滨在新诊断的非弥散性、内源性脑干胶质瘤和非弥散性高级别胶质瘤儿科患者中耐受性良好。 ISPECIFIC AIMS 主要目的: 1. 评估卡培他滨与放疗(RT)同时用于新诊断的非播散性、内源性脑干胶质瘤或新诊断的非播散性高级别胶质瘤儿童的最大耐受剂量(MTD)。 2. 描述卡培他滨与放疗同时给药治疗新诊断的非播散性、内源性脑干胶质瘤或新诊断的非播散性高级别胶质瘤儿童的剂量限制性毒性。 次要目的: 1. 在该儿科患者人群中表征卡培他滨速崩片给药后的卡培他滨药代动力学。 2. 在这项I期研究的背景下,描述卡培他滨和放疗在新诊断的非播散性、内源性脑干胶质瘤或新诊断的非播散性高级别胶质瘤儿童中观察到的抗肿瘤活性。 3. 采用MRI、MRS、灌注和扩散成像以及PET扫描表征接受放疗和卡培他滨治疗的非播散性、新诊断的脑干神经胶质瘤和高级别神经胶质瘤的影像学变化。 三. 背景和意义 脑干胶质瘤是发生在儿童和青少年的脑桥、中脑或髓质的星形细胞肿瘤。儿童期高级别星形细胞瘤是临床上侵袭性、区域性侵袭性肿瘤,儿童原发性脑干恶性胶质瘤的1年和5年无进展生存率(PFS)分别低于25%和10%。除放射治疗外,没有任何治疗对这些患者有益。化疗在治疗这种疾病中的作用尚不清楚。先前的研究表明,与单独的手术和放疗相比,增加化疗的益处充其量是适度的。显然,对于患有高级别神经胶质瘤的儿童,需要新的药物和新的治疗方法。 卡培他滨转化为5-氟尿嘧啶(5-FU),胸苷磷酸化酶(TP)作为肿瘤内活化的最终限速酶。先前的研究已经将卡培他滨的功效与细胞培养和人异种移植模型中的TP表达水平相关联。放射治疗是脑肿瘤治疗的标准组成部分,已显示在胶质母细胞瘤异种移植物中显著诱导TP。此外,卡培他滨已被证明是一种放射增敏剂以及针对转移性脑病变的活性单药。因此,评价卡培他滨联合放疗治疗原发性脑肿瘤有很强的理论依据。也可以实现有利的治疗指数,因为TP似乎在脑肿瘤中的表达量远大于正常脑组织。成人联合治疗的初步经验表明,治疗耐受性良好,未观察到意外或附加毒性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUSAN M. BLANEY其他文献

SUSAN M. BLANEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUSAN M. BLANEY', 18)}}的其他基金

PROTOCOL SPECIFIC RESEARCH SUPPORT
特定于协议的研究支持
  • 批准号:
    8181022
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:
CLINICAL TRIAL: A PHASE I STUDY OF MK-0752 IN PEDIATRIC PATIENTS WITH RECURREN
临床试验:MK-0752 在复发性儿科患者中的 I 期研究
  • 批准号:
    8356709
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:
CLINICAL TRIAL: PBTC-019: A PHASE I PHARMACOKINETIC OPTIMAL DOSING STUDY OF INT
临床试验:PBTC-019:INT 的 I 期药代动力学最佳剂量研究
  • 批准号:
    8356671
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:
CLINICAL TRIAL: A PHASE I TRIAL OF ESCALATING DOSES OF KARENITECIN PLUS CYCLOPH
临床试验:Karenitecin 加 CYCLOPH 剂量递增的 I 期试验
  • 批准号:
    8356684
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:
PBTC-025-A PHASE I PHARMACOPKINETIC AND SAFETY STUDY IN CHILDREN
PBTC-025-A 儿童 I 期药代动力学和安全性研究
  • 批准号:
    8356726
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:
A PHASE I STUDY OF ABT-888, AN ORAL INHIBITOR OF POLY
ABT-888(一种口服 POLY 抑制剂)的 I 期研究
  • 批准号:
    8356743
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:
CLINICAL TRIAL: PBTC-022 PHASE II STUDY OF BEVACIZUMAB PLUS IRINOTECAN (CAMPTOS
临床试验:贝伐珠单抗加伊立替康 (CAMPTOS) 的 PBTC-022 II 期研究
  • 批准号:
    8356679
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:
NANT 2007-02 - A PHASE I STUDY OF BEVACIZUMAB WITH BOLUS
NANT 2007-02 - 贝伐珠单抗推注的 I 期研究
  • 批准号:
    8356742
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:
CLINICAL TRIAL: A PHASE II TRIAL OF CAPECITABINE RAPIDLY DISINTEGRATING TABLETS
临床试验:卡培他滨快速崩解片的 II 期试验
  • 批准号:
    8356747
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:
DATA SAFETY AND MONITORING BOARD
数据安全和监控委员会
  • 批准号:
    8181025
  • 财政年份:
    2010
  • 资助金额:
    $ 0.24万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 0.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了